文献速递痛风与晶体性关节病

超声显示痛风达标治疗中晶体沉积快速减少:NOR-Gout 研究12个月结果

Ultrasound shows rapid reduction of crystal depositions during a treat-to-target approach in gout patients: 12-month results from the NOR-Gout study.
PubMed 文献 · Ann Rheum Dis · 2020-07-15

该单中心研究纳入209例近期痛风发作患者,采用达标治疗策略降尿酸,在基线及3、6、12个月对双侧手、肘、膝、踝、足关节/肌腱/附着点行超声检查,用0-3半定量评分评估双轨征、痛风石和聚集体的沉积量。结果显示血尿酸从基线500 µmol/L降至12个月312 µmol/L(p<0.001),双轨征、痛风石和聚集体评分均显著下降(p<0.001),双轨征对变化最敏感。

要点

  • 达标降尿酸治疗12个月可显著减少痛风患者超声可见的晶体沉积。
  • 双轨征是超声评估晶体沉积变化最敏感的指标。
  • 第一跖趾关节是各基本病变最常见部位,侵蚀与更高晶体沉积相关。

核心结论

  • 超声晶体沉积评分对变化敏感,达标降尿酸治疗使所有沉积显著减少,以双轨征减少最明显。

研究设计与样本

  • 单中心研究连续纳入近期痛风发作患者,采用达标治疗策略降尿酸,在基线及3、6、12个月行双侧超声检查。
  • 对209例基线超声评估患者(平均年龄56.4岁,病程7.9年,95.2%男性)应用0-3半定量评分评估双轨征、痛风石和聚集体。

主要发现

  • 血尿酸从基线500 µmol/L降至12个月312 µmol/L(p<0.001)。
  • 从基线至12个月,平均总评分双轨征从4.3降至1.3、痛风石从6.5降至3.8、聚集体从9.3降至6.7(均p<0.001)。
  • 第一跖趾关节是所有基本病变最常见部位,侵蚀与更高水平晶体沉积相关。

关键数值与推荐

  • 超声半定量评分系统为0-3分,评估双轨征、痛风石和聚集体。
  • 双轨征对变化最敏感。

临床怎么用

  • 达标降尿酸治疗过程中可用超声半定量评分动态监测晶体沉积溶解情况。
  • 双轨征可作为评估治疗反应的首选超声指标。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: As ultrasound is sensitive for detecting crystal depositions in patients with gout, our objectives were to explore the main locations for depositions and the extent of dissolution of depositions during a treat-to-target approach with urate lowering treatment (ULT) in patients with gout. METHODS: Patients with a recent flare of gout were consecutively included in this single-centre study and managed by a treat-to-target approach with ULT. All patients were assessed at baseline, 3, 6 and 12 months including bilateral ultrasound examinations of joints/tendons/entheses of hands, elbows, knees, ankles and feet. A new semiquantitative scoring system of 0-3 of elementary lesions (double contour (DC), tophi and aggregates) was applied to quantify the amount of depositions during the follow-up. RESULTS: 209 of the patients were evaluated with ultrasound at baseline (mean (SD) age 56.4 (13.8) years and disease duration 7.9 (7.7) years, 95.2% men). The serum urate levels decreased from baseline to 12 months (mean (SD) 500 (77) to 312 (49) µmol/L) (p<0.001)). The first metatarsophalangeal joint was the most frequent location for all the elementary lesions and erosions were associated with higher levels of crystal depositions. From baseline to 12 months, mean sum scores decreased for DC (4.3 to 1.3), tophi (6.5 to 3.8) and aggregates (9.3 to 6.7) (p<0.001 for all), with DC being most sensitive to change. CONCLUSIONS: The ultrasound scoring system for crystal depositions was sensitive to change and showed that a treat-to-target approach with ULT resulted in significant reductions of all the depositions, most extensively for DC.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Hammer HB, Karoliussen L, Terslev L, et al. Ultrasound shows rapid reduction of crystal depositions during a treat-to-target approach in gout patients: 12-month results from the NOR-Gout study. Ann Rheum Dis. 2020. PMID: 32669301. doi:10.1136/annrheumdis-2020-217392

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。